156 related articles for article (PubMed ID: 28935190)
1. A roadmap for cost-of-goods planning to guide economic production of cell therapy products.
Lipsitz YY; Milligan WD; Fitzpatrick I; Stalmeijer E; Farid SS; Tan KY; Smith D; Perry R; Carmen J; Chen A; Mooney C; Fink J
Cytotherapy; 2017 Dec; 19(12):1383-1391. PubMed ID: 28935190
[TBL] [Abstract][Full Text] [Related]
2. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
3. Putting a price tag on novel autologous cellular therapies.
Abou-El-Enein M; Bauer G; Medcalf N; Volk HD; Reinke P
Cytotherapy; 2016 Aug; 18(8):1056-1061. PubMed ID: 27288308
[TBL] [Abstract][Full Text] [Related]
4. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
Harrison RP; Rafiq QA; Medcalf N
Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
[TBL] [Abstract][Full Text] [Related]
5. Impact considerations of post-production processes on cell and gene drug products.
Fink J; Scott M; Rieck S; Jones R; Parisse JS; Hagen H; Lipsitz Y; Oh S; Clarke D
Cytotherapy; 2022 Jun; 24(6):583-589. PubMed ID: 35643522
[TBL] [Abstract][Full Text] [Related]
6. Towards a common framework for defining ancillary material quality across the development spectrum.
Ball O; Zylberberg C
Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
[TBL] [Abstract][Full Text] [Related]
7. Process change evaluation framework for allogeneic cell therapies: impact on drug development and commercialization.
Hassan S; Huang H; Warren K; Mahdavi B; Smith D; Jong S; Farid SS
Regen Med; 2016 Apr; 11(3):287-305. PubMed ID: 26979513
[TBL] [Abstract][Full Text] [Related]
8. Short Time to Market and Forward Planning Will Enable Cell Therapies to Deliver R&D Pipeline Value.
Krishna D; Rittié L; Tran H; Zheng X; Chen-Rogers CE; McGillivray A; Clay T; Ketkar A; Tarnowski J
Hum Gene Ther; 2021 May; 32(9-10):433-445. PubMed ID: 33023309
[TBL] [Abstract][Full Text] [Related]
9. Modeling biological and economic uncertainty on cell therapy manufacturing: the choice of culture media supplementation.
Bandeiras C; Cabral JM; Finkelstein SN; Ferreira FC
Regen Med; 2018 Dec; 13(8):917-933. PubMed ID: 30488770
[TBL] [Abstract][Full Text] [Related]
10. Towards Automated Manufacturing for Cell Therapies.
Smith D; Heathman TRJ; Klarer A; LeBlon C; Tada Y; Hampson B
Curr Hematol Malig Rep; 2019 Aug; 14(4):278-285. PubMed ID: 31254154
[TBL] [Abstract][Full Text] [Related]
11. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
Hourd P; Ginty P; Chandra A; Williams DJ
Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
[TBL] [Abstract][Full Text] [Related]
12. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
[No Abstract] [Full Text] [Related]
13. Assessing commercial opportunities for autologous and allogeneic cell-based products.
Smith DM
Regen Med; 2012 Sep; 7(5):721-32. PubMed ID: 22954441
[TBL] [Abstract][Full Text] [Related]
14. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P
Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061
[TBL] [Abstract][Full Text] [Related]
15. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.
Wang K; Liu Y; Li J; Wang B; Bishop R; White C; Das A; Levine AD; Ho L; Levine BL; Fesnak AD
Cytotherapy; 2019 Oct; 21(10):1081-1093. PubMed ID: 31445816
[TBL] [Abstract][Full Text] [Related]
16. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
17. Estimation of manufacturing development costs of cell-based therapies: a feasibility study.
Ten Ham RMT; Nievaart JC; Hoekman J; Cooper RS; Frederix GWJ; Leufkens HGM; Klungel OH; Ovelgönne H; Hoefnagel MHN; Turner ML; Mountford JC
Cytotherapy; 2021 Aug; 23(8):730-739. PubMed ID: 33593688
[TBL] [Abstract][Full Text] [Related]
18. Avoiding Stops and Overcoming Roadblocks: Considerations for Improving Patient Access to CAR-Based Cell Therapies.
Laskowski TJ; Daher M; Basar R; Rezvani K
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-5. PubMed ID: 33989022
[TBL] [Abstract][Full Text] [Related]
19. Reimbursement and adoption of advanced therapies: the 5-C framework.
Malik NN
Regen Med; 2014; 9(5):573-8. PubMed ID: 25372076
[No Abstract] [Full Text] [Related]
20. The Biobank Economic Modeling Tool (BEMT): Online Financial Planning to Facilitate Biobank Sustainability.
Odeh H; Miranda L; Rao A; Vaught J; Greenman H; McLean J; Reed D; Memon S; Fombonne B; Guan P; Moore HM
Biopreserv Biobank; 2015 Dec; 13(6):421-9. PubMed ID: 26697911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
